Drug Profile
Research programme: anti-infectives - Zymenex
Alternative Names: ACE 710; ACE 810; ACE 820; Anti-infectives research programme - ZymenexLatest Information Update: 24 Jan 2018
Price :
$50
*
At a glance
- Originator ACE BioSciences
- Developer Zymenex A/S
- Class Antibodies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Aspergillosis; Clostridium difficile infections; Moraxella infections
Most Recent Events
- 24 Jan 2018 Discontinued - Preclinical for Aspergillosis in USA (Parenteral) (Zymenex pipeline, January 2018)
- 24 Jan 2018 Discontinued for Clostridium difficile infections in USA (Parenteral) (Zymenex pipeline, January 2018)
- 24 Jan 2018 Discontinued for Moraxella infections in USA (Parenteral) (Zymenex pipeline, January 2018)